Assessment of Beta blocker interruption after uncomplicated mYocardial infarction on Safety and Symptomatic cardiac events requiring hospitalization: The ABYSS Study - ABYSS

Overview

No summary available.

Registry

who.int

Start Date

October 13, 2017

End Date

TBD

Last Updated

7 years ago

Study Type

Interventional clinical trial of medicinal product

Sponsor

•1\. Male or female \> or\= 18 years of age
•2\. Current treatment with BB whatever the drug or the dose used
•3\. Prior documented acute myocardial infarction 6 months or more before randomisation defined either by:
•\- a documented ST elevation MI with ST segment elevation (STEMI) and/or the presence of Q wave (Type I MI)
•\- a documented episode of Non ST Elevation MI (NSTEMI) with at least one of the followings:
•i) a documented hypokinetic or akinetic segment on echo or any other imaging technique
•ii) segmental hypoperfusion Thallium or any other imaging technique
•iii) segmental aspect of necrosis on MRI
•4\. Patient affiliated to Social Security
•5\. Informed consent obtained in writing at enrolment into the study

•1\. Uncontrolled arterial hypertension according to investigator decision
•2\. Prior episode of heart failure in the past two years of follow\-up and/or low left ventricular ejection fraction \<40% requiring the use of BB
•3\. New ACS (in the past 6 months) including UA/NSTEMI and STEMI
•4\. Persistent angina or ischemia (\>10% viable myocardium) requiring the use of BB
•5\. Prior episode of ventricular or supraventricular arrhythmia in the past year of follow\-up requiring the use of BB
•6\. Treatment with other investigational agents or devices (randomisation) within the previous 30 days, or previous enrolment in this trial.